Objective Accelerated atherosclerosis remains the major cause of late death (after 5 years) in SLE. Yet, the ‘traditional’ cardiovascular risk equations (such as Framingham) consistently underestimate ...

Systemic lupus erythematosus (SLE) is the most common form of lupus; however, the development of new drugs for SLE has been limited, with only two drugs approved in the past 60 years. Recently, the ...

Background and aims Preliminary data suggested efficacy of sirolimus in treatment of lupus nephritis (LN), but its long-term efficacy and tolerability data is lacking. Methods We reviewed Class III/IV ...

Background and Aims Iguratimod (IGT) is a small molecular immunomodulatory drug and has been approved for treating rheumatoid arthritis. In our previous work, IGT ameliorates lupus-like disease in MRL ...

Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus and lupus nephritis (LN) have not meet their primary endpoints (Arthritis Rheum 2012;64:1215 and ...

Winberg et al 1 present important new information on a story that began with the discovery of the lupus erythematosus (LE) cell phenomenon. As described in a truly landmark paper, Hargraves and ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

Background Epigenetic dysregulation is implicated in the pathogenesis of lupus. We performed a longitudinal analysis of DNA methylation in lupus patients and assessed epigenetic changes over time and ...

Background Subcutaneous (SC) administration of KZR-616 (30 and 45 mg weekly [QW]) was demonstrated as safe and well-tolerated, and successfully achieved target levels of immunoproteasome inhibition in ...

Background and aims IFNα, produced by plasmacytoid dendritic cells (pDCs) is a major contributor to SLE pathogenesis. IL-3 promotes pDC survival, but its role in SLE has not been well characterised.

Objective The objective of this research is to identify metabolic markers associated with successful treatment by evaluating the effect of mesenchymal stem cell transplantation (MSCT) on the metabolic ...

Introduction Mycophenolic acid (MPA) is a primary immunosuppressive agent used in the treatment of lupus nephritis (LN). While therapeutic drug monitoring (TDM) of MPA is well established in organ ...